Amgen Inc. v. Sanofi
View Official PDFSummary
A short, plain-English overview of Amgen Inc. v. Sanofi.
The Supreme Court reviewed a case involving Amgen Inc. and Sanofi concerning patents for antibodies that reduce LDL cholesterol. Amgen's 2014 patents claimed a broad class of antibodies, but the courts found these claims invalid under the Patent Act's enablement requirement. The Court affirmed that Amgen's methods did not sufficiently enable skilled individuals to make and use the entire class of antibodies claimed.
Holding
The single most important “bottom line” of what the Court decided in Amgen Inc. v. Sanofi.
The Court held that Amgen failed to enable any person skilled in the art to make and use the invention as defined by the relevant claims.
Key Quotes
Short excerpts from the syllabus in Amgen Inc. v. Sanofi that support the summary and concepts above.
Amgen's claims sweep much broader than the 26 exemplary antibodies it identifies by their amino acid sequences.
The 'roadmap' merely describes step-by-step Amgen's own trial-and-error method for finding functional antibodies.
Amgen's alternative arguments lack merit.
